Latest Articlesddd

Sorrento Therapeutics Releases Preclinical Data from STI-1499 and STI-2020 Demonstrating Potent Neutralizing Antibodies Against SARS-CoV-2

September 29, 2020 0

Sorrento Therapeutics Preclinical Data of Neutralizing Antibodies Against SARS-CoV-2 In preclinical studies, both STI-1499 and STI-2020 …

Johnson & Johnson Launches a Large Scale Phase 3 Trial of Its COVID-19 Vaccine. See Also: Intellia to Prove the Advantages of CRISPR Gene-Editing

September 29, 2020 0

Johnson & Johnson ENSEMBLE Trial for Its COVID-19 Vaccine Candidate Johnson & Johnson (JNJ) announced the …

The Whole World Against the Blind SARS-CoV-2 Virus

September 28, 2020 3

Prohost Letter 442 The Whole World Against the Blind SARS-CoV-2 Virus Investors have no doubt profited …

Revolution Medicines Inc Has Revolutionary News

September 25, 2020 0

Revolution Medicines Inc Revolution Medicines (RVMD) is a clinical-stage precision oncology company focused on developing targeted …

Amgen’s KRAS G12C Inhibitor Product Sotorasib Has Thrilling Results

September 25, 2020 0

Amgen and the KRAS G12C Protein Discovery The RAS gene family has been a subject for four decades …

The EMA Granted PRIME Designation to CRISPR Therapeutics’ and Vertex Pharmaceuticals’ Product CTX001™ for Severe SCD

September 22, 2020 0

Crispr Therapeutics and Vertex Pharmaceuticals CTX001 Granted PRIME Designation by the EMA CRISPR Therapeutics (CRSP) and …

Eli Lilly Neutralizing Antibody LY-CoV555 Promises a Reduction in the Rate of COVID-19 Hospitalizations  

September 16, 2020 0

Eli Lilly and AbCellera Collaboration Result LY-C0V555  A lot of discoveries, followed by thorough experimentation beyond …

Seattle Genetics: Two New Oncology Collaborations with Merck

September 14, 2020 0

Seattle Genetics Two New Strategic Oncology Collaborations with Merck Seattle Genetics (SGEN) and Merck (

Cassava Sciences Promising and Encouraging Results of Its Alzheimer’s Disease Product Sumifilam

September 14, 2020 0

Cassava Sciences Study Results of Sumifilam for Alzheimer's Disease Prohost is happy to inform our subscribers …

Gilead Sciences Could Acquire Immunomedics at $20 Billion. See Also: AstraZeneca Vaccine Trial Resumed

September 12, 2020 0

Gilead Sciences News Is Not Just Gossip Real news, not just gossip, is spreading today about …

Agenus Stock Rallied Yesterday

September 11, 2020 0

Why Agenus Stock Rallied Yesterday On September 2, 2020 we posted an article about Agenus (AGEN) …

From Inovio: Thermo Fisher Scientific Will Manufacture the Inovio COVID-19 Vaccine Candidate

September 9, 2020 0

Inovio COVID-19 Vaccine Candidate Will be Manufactured by Thermo Fisher Scientific Thermo Fisher Scientific (TMO) joins …

Compugen Has Encouraging News

September 8, 2020 0

Compugen Announced Encouraging News from Its Phase 1/2 Study of COM701 Compugen (CGEN) announced that the …

Sanofi and GlaxoSmithKLine COVID-19 Vaccines are Advancing in Clinical Trial

September 3, 2020 0

Sanofi and GlaxoSmithKline Have COVID-19 Vaccines Advancing in Clinical Trial Sanofi (SNY) and GlaxoSmithKline (GSK) started …

The U.S. CDC Tells the 50 States to Prepare for COVID-19 Vaccines by the End of October

September 3, 2020 0

CDC Is Asking States to Prepare for COVID-19 Vaccines The U.S. Center of Disease Control and …

Agenus: Could It Be a Resurrection? See Also: Prohost Performing Stocks

September 2, 2020 0

Agenus Announced Data from Phase 2 Trials of Balstilimab Agenus (AGEN) immuno-oncology company announced that data …

Moderna Inc Stock is Tanking After Rallying

September 1, 2020 0

Moderna Inc Late August Announcements  On August 28, 2020 Moderna Inc (MRNA) issued a press release …

Why The Time Has Come for Rhythm Pharmaceuticals to Outperform

August 28, 2020 0

Rhythm Pharmaceuticals Inc Rhythm Pharmaceuticals (RYTM) is a late-stage biopharmaceutical company with a product pipeline that …

Moderna Encouraging News. See Also: Translate Bio and Sanofi Good News

August 27, 2020 0

Moderna Presented Interim Clinical Data about mRNA-1273 for COVID-19 Moderna (MRNA) presented new Interim Clinical Data …

Exelixis Announces Submission of sNDA to U.S. FDA for Cabozantinib in Combination with Nivolumab for Advanced RCC

August 25, 2020 0

Exelixis Announces Submission of sNDA to US FDA for CABOMETYX® Exelixis (EXEL) announced the submission of …